RxDoctor Payments Data

Lindsay Barnard

Family · Clyo, GANPI 1083387690

Payments from drug & device makers

$5,947in general payments, 2019–2025

Across 196 payments — averaging $30.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Merck$638
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$473
  • Novartis$414
  • AstraZeneca$348
  • Boston Scientific$338
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$1,69028%
  • Food & beverage$4,23971%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,947 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$13,030
Medicare patients
110
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan117$89,010
EliquisApixaban101$69,149
XareltoRivaroxaban29$18,070
FarxigaDapagliflozin Propanediol18$16,660
VerquvoVericiguat24$16,613
Repatha SureclickEvolocumab11$6,418
Flecainide Acetate53$2,037
Nifedipine ErNifedipine88$1,823
Metoprolol Succinate156$934
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$836
Ranolazine ErRanolazine25$823
Amiodarone Hcl17$718
Carvedilol115$510
Potassium Chloride52$457
Bisoprolol Fumarate17$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$414$89,010117 claims
PfizerEliquis$69$69,149101 claims
Johnson & JohnsonXarelto$53$18,07029 claims
AstraZenecaFarxiga$348$16,66018 claims
MerckVerquvo$638$16,61324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Clyo

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →